Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706490 | 0.90 | TP53 (0.46) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL4702228 | 0.83 | TP53 (0.38) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL5996329 | 0.81 | TP53 (0.40) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL22690756 | 0.81 | MAPT (0.41) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL22691455 | 0.81 | MAPT (0.41) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL22690753 | 0.81 | MAPT (0.41) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL4704261 | 0.80 | MAPT (0.39) | TP53MAPTPOLBRXFP1KDM4E | |
| Hydrochloric Acid SCHEMBL5996085 | 0.80 | MAPT (0.41) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL5996075 | 0.80 | TP53 (0.41) | TP53MAPTPOLBRXFP1KDM4E | |
| SCHEMBL4703719 | 0.77 | RORC (0.36) | TP53MAPTPOLBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | TP53 580/4885MAPT 434/4885POLB 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.